You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Where Are We Now in Managing Patients With SLE During the COVID-19 Pandemic?

  • Authors: Ronald van Vollenhoven, MD, PhD; Marta Mosca, MD, PhD
  • CPD Released: 7/29/2020
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 7/29/2021, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US primary care physicians, rheumatologists, and nephrologists.

The goal of this activity is to increase knowledge on the management of patients with systemic lupus erythematosus (SLE) during the COVID-19 era.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Latest information on COVID-19 and its impact on patients with SLE
    • Rheumatological care for patients with SLE in a COVID era


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Ronald van Vollenhoven, MD, PhD

    Professor of Rheumatology
    Amsterdam University Medical Centers
    Amsterdam, the Netherlands

    Disclosures

    Disclosure: Ronald van Vollenhoven, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie Inc.; AstraZeneca Pharmaceuticals LP; Biogen; Biotest; Celgene Corporation; Glapagos; Gilead Sciences, Inc.; Janssen Pharmaceuticals; Pfizer Inc.; SERVIER; UCB Pharma, Inc.
    Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Galapagos; Janssen Pharmaceuticals; Pfizer Inc.; UCB Pharma, Inc.
    Received grants for clinical research from: Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; UCB Pharma, Inc.

  • Marta Mosca, MD, PhD

    Associate Professor of Rheumatology
    University of Pisa
    Pisa, Italy

    Disclosures

    Disclosure: Marta Mosca, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Eli Lilly and Company; UCB Pharma, Inc.
    Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Bristol-Myers Squibb Company; Sanofi
    Received grants for clinical research from: Pfizer Inc.

Editor

  • Shanthi Voorn, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Shanthi Voorn, PhD, has disclosed no relevant financial relationships.

Content Reviewer

  • Esther Nyarko, PharmD

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.25 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Where Are We Now in Managing Patients With SLE During the COVID-19 Pandemic?

Authors: Ronald van Vollenhoven, MD, PhD; Marta Mosca, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 7/29/2020

Valid for credit through: 7/29/2021, 11:59 PM EST

processing....

 

 

  • Print